nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—S100B—vertebral column—psoriasis	0.0435	0.334	CbGeAlD
Olopatadine—CYP3A4—Calcitriol—psoriasis	0.0421	0.191	CbGbCtD
Olopatadine—S100A2—skin epidermis—psoriasis	0.0335	0.257	CbGeAlD
Olopatadine—CYP3A4—Methoxsalen—psoriasis	0.0327	0.149	CbGbCtD
Olopatadine—CYP3A4—Cholecalciferol—psoriasis	0.0217	0.0986	CbGbCtD
Olopatadine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0188	0.0855	CbGbCtD
Olopatadine—CYP3A4—Triamcinolone—psoriasis	0.0188	0.0855	CbGbCtD
Olopatadine—CYP3A4—Betamethasone—psoriasis	0.0161	0.0734	CbGbCtD
Olopatadine—CYP3A4—Prednisolone—psoriasis	0.0159	0.0724	CbGbCtD
Olopatadine—CYP3A4—Hydrocortisone—psoriasis	0.0151	0.0686	CbGbCtD
Olopatadine—CYP3A4—Prednisone—psoriasis	0.015	0.0684	CbGbCtD
Olopatadine—CYP3A4—Cyclosporine—psoriasis	0.0143	0.0648	CbGbCtD
Olopatadine—S100A2—skin of body—psoriasis	0.0104	0.0798	CbGeAlD
Olopatadine—S100A1—skin of body—psoriasis	0.00956	0.0735	CbGeAlD
Olopatadine—CYP3A4—Dexamethasone—psoriasis	0.00939	0.0427	CbGbCtD
Olopatadine—S100A13—Vitamin A—Acitretin—psoriasis	0.00905	1	CbGdCrCtD
Olopatadine—S100A13—skin of body—psoriasis	0.00849	0.0652	CbGeAlD
Olopatadine—S100B—skin of body—psoriasis	0.00826	0.0635	CbGeAlD
Olopatadine—S100A2—tendon—psoriasis	0.00791	0.0607	CbGeAlD
Olopatadine—S100A1—tendon—psoriasis	0.00728	0.0559	CbGeAlD
Olopatadine—HRH1—tendon—psoriasis	0.00129	0.00991	CbGeAlD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—NFKBIA—psoriasis	0.00104	0.00463	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKBIA—psoriasis	0.00104	0.00463	CbGpPWpGaD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—NFKBIA—psoriasis	0.00102	0.00454	CbGpPWpGaD
Olopatadine—S100A12—Toll-Like Receptors Cascades—SOCS1—psoriasis	0.00102	0.00453	CbGpPWpGaD
Olopatadine—S100B—MyD88 cascade initiated on plasma membrane—NFKBIA—psoriasis	0.000995	0.00441	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—NFKBIA—psoriasis	0.000988	0.00438	CbGpPWpGaD
Olopatadine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKBIA—psoriasis	0.000986	0.00437	CbGpPWpGaD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—NFKBIA—psoriasis	0.000971	0.00431	CbGpPWpGaD
Olopatadine—S100B—MyD88 dependent cascade initiated on endosome—NFKBIA—psoriasis	0.000968	0.00429	CbGpPWpGaD
Olopatadine—S100B—Toll-Like Receptors Cascades—SOCS1—psoriasis	0.000965	0.00428	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—TYK2—psoriasis	0.000952	0.00423	CbGpPWpGaD
Olopatadine—S100A12—Immune System—KIR2DS1—psoriasis	0.000945	0.00419	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 9 (TLR9) Cascade—NFKBIA—psoriasis	0.000934	0.00414	CbGpPWpGaD
Olopatadine—S100A12—MyD88-independent cascade—NFKBIA—psoriasis	0.000931	0.00413	CbGpPWpGaD
Olopatadine—S100B—MyD88:Mal cascade initiated on plasma membrane—NFKBIA—psoriasis	0.000918	0.00407	CbGpPWpGaD
Olopatadine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—TYK2—psoriasis	0.000901	0.004	CbGpPWpGaD
Olopatadine—S100B—Immune System—KIR2DS1—psoriasis	0.000893	0.00396	CbGpPWpGaD
Olopatadine—S100B—MyD88-independent cascade—NFKBIA—psoriasis	0.000881	0.00391	CbGpPWpGaD
Olopatadine—S100A2—Direct p53 effectors—TP53—psoriasis	0.00087	0.00386	CbGpPWpGaD
Olopatadine—S100A12—MyD88 cascade initiated on plasma membrane—TYK2—psoriasis	0.000862	0.00382	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—TYK2—psoriasis	0.000854	0.00379	CbGpPWpGaD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—TYK2—psoriasis	0.000838	0.00372	CbGpPWpGaD
Olopatadine—S100A12—Activated TLR4 signalling—NFKBIA—psoriasis	0.000838	0.00372	CbGpPWpGaD
Olopatadine—S100A12—Cytosolic sensors of pathogen-associated DNA—NFKB1—psoriasis	0.000822	0.00365	CbGpPWpGaD
Olopatadine—S100B—MyD88 cascade initiated on plasma membrane—TYK2—psoriasis	0.000815	0.00362	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—TYK2—psoriasis	0.000809	0.00359	CbGpPWpGaD
Olopatadine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—TYK2—psoriasis	0.000807	0.00358	CbGpPWpGaD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—TYK2—psoriasis	0.000795	0.00353	CbGpPWpGaD
Olopatadine—S100B—MyD88 dependent cascade initiated on endosome—TYK2—psoriasis	0.000793	0.00352	CbGpPWpGaD
Olopatadine—S100B—Activated TLR4 signalling—NFKBIA—psoriasis	0.000792	0.00352	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—NFKBIA—psoriasis	0.000788	0.0035	CbGpPWpGaD
Olopatadine—S100B—Cytosolic sensors of pathogen-associated DNA—NFKB1—psoriasis	0.000777	0.00345	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—JUN—psoriasis	0.000771	0.00342	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 9 (TLR9) Cascade—TYK2—psoriasis	0.000765	0.00339	CbGpPWpGaD
Olopatadine—S100A12—MyD88-independent cascade—TYK2—psoriasis	0.000763	0.00338	CbGpPWpGaD
Olopatadine—S100B—MyD88:Mal cascade initiated on plasma membrane—TYK2—psoriasis	0.000752	0.00334	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—NFKBIA—psoriasis	0.000745	0.00331	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—NFKB1—psoriasis	0.000742	0.00329	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—DDX58—psoriasis	0.000731	0.00324	CbGpPWpGaD
Olopatadine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—JUN—psoriasis	0.000729	0.00324	CbGpPWpGaD
Olopatadine—S100B—MyD88-independent cascade—TYK2—psoriasis	0.000721	0.0032	CbGpPWpGaD
Olopatadine—S100A12—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—NFKB1—psoriasis	0.000705	0.00313	CbGpPWpGaD
Olopatadine—S100A12—Toll-Like Receptors Cascades—NFKBIA—psoriasis	0.000702	0.00311	CbGpPWpGaD
Olopatadine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—NFKB1—psoriasis	0.000702	0.00311	CbGpPWpGaD
Olopatadine—S100A12—MyD88 cascade initiated on plasma membrane—JUN—psoriasis	0.000697	0.0031	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—DDX58—psoriasis	0.000691	0.00307	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—JUN—psoriasis	0.000691	0.00307	CbGpPWpGaD
Olopatadine—S100A12—Activated TLR4 signalling—TYK2—psoriasis	0.000686	0.00304	CbGpPWpGaD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—JUN—psoriasis	0.000678	0.00301	CbGpPWpGaD
Olopatadine—S100A12—MyD88 cascade initiated on plasma membrane—NFKB1—psoriasis	0.000671	0.00298	CbGpPWpGaD
Olopatadine—S100B—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—NFKB1—psoriasis	0.000666	0.00296	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKB1—psoriasis	0.000665	0.00295	CbGpPWpGaD
Olopatadine—S100B—Toll-Like Receptors Cascades—NFKBIA—psoriasis	0.000664	0.00294	CbGpPWpGaD
Olopatadine—S100B—MyD88 cascade initiated on plasma membrane—JUN—psoriasis	0.00066	0.00293	CbGpPWpGaD
Olopatadine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000656	0.00291	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—JUN—psoriasis	0.000655	0.00291	CbGpPWpGaD
Olopatadine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—JUN—psoriasis	0.000653	0.0029	CbGpPWpGaD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—NFKB1—psoriasis	0.000653	0.0029	CbGpPWpGaD
Olopatadine—S100B—Activated TLR4 signalling—TYK2—psoriasis	0.000649	0.00288	CbGpPWpGaD
Olopatadine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000647	0.00287	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—TYK2—psoriasis	0.000645	0.00286	CbGpPWpGaD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—JUN—psoriasis	0.000644	0.00286	CbGpPWpGaD
Olopatadine—S100B—MyD88 dependent cascade initiated on endosome—JUN—psoriasis	0.000642	0.00285	CbGpPWpGaD
Olopatadine—S100B—MyD88 cascade initiated on plasma membrane—NFKB1—psoriasis	0.000635	0.00282	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—NFKB1—psoriasis	0.00063	0.0028	CbGpPWpGaD
Olopatadine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NFKB1—psoriasis	0.000629	0.00279	CbGpPWpGaD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—NFKB1—psoriasis	0.000619	0.00275	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 9 (TLR9) Cascade—JUN—psoriasis	0.000619	0.00275	CbGpPWpGaD
Olopatadine—S100B—MyD88 dependent cascade initiated on endosome—NFKB1—psoriasis	0.000618	0.00274	CbGpPWpGaD
Olopatadine—S100A12—MyD88-independent cascade—JUN—psoriasis	0.000617	0.00274	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—TYK2—psoriasis	0.00061	0.00271	CbGpPWpGaD
Olopatadine—S100B—MyD88:Mal cascade initiated on plasma membrane—JUN—psoriasis	0.000609	0.0027	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 9 (TLR9) Cascade—NFKB1—psoriasis	0.000596	0.00264	CbGpPWpGaD
Olopatadine—S100A12—MyD88-independent cascade—NFKB1—psoriasis	0.000594	0.00264	CbGpPWpGaD
Olopatadine—S100B—MyD88:Mal cascade initiated on plasma membrane—NFKB1—psoriasis	0.000586	0.0026	CbGpPWpGaD
Olopatadine—S100B—MyD88-independent cascade—JUN—psoriasis	0.000584	0.00259	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—SOCS1—psoriasis	0.000581	0.00258	CbGpPWpGaD
Olopatadine—S100A12—Toll-Like Receptors Cascades—TYK2—psoriasis	0.000575	0.00255	CbGpPWpGaD
Olopatadine—S100B—MyD88-independent cascade—NFKB1—psoriasis	0.000562	0.00249	CbGpPWpGaD
Olopatadine—S100A12—Activated TLR4 signalling—JUN—psoriasis	0.000555	0.00246	CbGpPWpGaD
Olopatadine—S100B—Toll-Like Receptors Cascades—TYK2—psoriasis	0.000544	0.00241	CbGpPWpGaD
Olopatadine—S100A12—Activated TLR4 signalling—NFKB1—psoriasis	0.000535	0.00237	CbGpPWpGaD
Olopatadine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000532	0.00236	CbGpPWpGaD
Olopatadine—S100B—Activated TLR4 signalling—JUN—psoriasis	0.000525	0.00233	CbGpPWpGaD
Olopatadine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000524	0.00233	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—JUN—psoriasis	0.000522	0.00232	CbGpPWpGaD
Olopatadine—S100B—Signaling by ERBB4—TYK2—psoriasis	0.000512	0.00227	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—IL4—psoriasis	0.000507	0.00225	CbGpPWpGaD
Olopatadine—S100B—Activated TLR4 signalling—NFKB1—psoriasis	0.000506	0.00224	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IFIH1—psoriasis	0.000503	0.00223	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—NFKB1—psoriasis	0.000503	0.00223	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000498	0.00221	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—JUN—psoriasis	0.000494	0.00219	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ERAP1—psoriasis	0.000484	0.00215	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—HLA-C—psoriasis	0.000477	0.00212	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IFIH1—psoriasis	0.000476	0.00211	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—NFKB1—psoriasis	0.000476	0.00211	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—TNFAIP3—psoriasis	0.000471	0.00209	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—psoriasis	0.000466	0.00207	CbGpPWpGaD
Olopatadine—S100A12—Toll-Like Receptors Cascades—JUN—psoriasis	0.000465	0.00206	CbGpPWpGaD
Olopatadine—S100B—Immune System—ERAP1—psoriasis	0.000457	0.00203	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—HLA-C—psoriasis	0.000451	0.002	CbGpPWpGaD
Olopatadine—S100A12—Toll-Like Receptors Cascades—NFKB1—psoriasis	0.000448	0.00199	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—TNFAIP3—psoriasis	0.000445	0.00198	CbGpPWpGaD
Olopatadine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—psoriasis	0.000441	0.00195	CbGpPWpGaD
Olopatadine—S100B—Toll-Like Receptors Cascades—JUN—psoriasis	0.00044	0.00195	CbGpPWpGaD
Olopatadine—S100A12—Immune System—DDX58—psoriasis	0.000426	0.00189	CbGpPWpGaD
Olopatadine—S100B—Toll-Like Receptors Cascades—NFKB1—psoriasis	0.000424	0.00188	CbGpPWpGaD
Olopatadine—S100A12—MyD88 cascade initiated on plasma membrane—IL6—psoriasis	0.000421	0.00187	CbGpPWpGaD
Olopatadine—S100A12—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—psoriasis	0.000418	0.00185	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—HCAR2—psoriasis	0.000412	0.00183	CbGpPWpGaD
Olopatadine—S100A12—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	0.00041	0.00182	CbGpPWpGaD
Olopatadine—S100B—Immune System—DDX58—psoriasis	0.000403	0.00179	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—NFKBIA—psoriasis	0.000399	0.00177	CbGpPWpGaD
Olopatadine—S100B—MyD88 cascade initiated on plasma membrane—IL6—psoriasis	0.000399	0.00177	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—HLA-E—psoriasis	0.000396	0.00176	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	0.000396	0.00176	CbGpPWpGaD
Olopatadine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—psoriasis	0.000395	0.00175	CbGpPWpGaD
Olopatadine—S100A12—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	0.000389	0.00173	CbGpPWpGaD
Olopatadine—S100B—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	0.000388	0.00172	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—HCAR2—psoriasis	0.000379	0.00168	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—HLA-E—psoriasis	0.000374	0.00166	CbGpPWpGaD
Olopatadine—S100B—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	0.000374	0.00166	CbGpPWpGaD
Olopatadine—S100A12—MyD88-independent cascade—IL6—psoriasis	0.000373	0.00166	CbGpPWpGaD
Olopatadine—S100B—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	0.000368	0.00163	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TAGAP—psoriasis	0.000357	0.00158	CbGpPWpGaD
Olopatadine—S100B—MyD88-independent cascade—IL6—psoriasis	0.000353	0.00157	CbGpPWpGaD
Olopatadine—S100A12—Activated TLR4 signalling—IL6—psoriasis	0.000336	0.00149	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—SOCS1—psoriasis	0.000331	0.00147	CbGpPWpGaD
Olopatadine—HRH1—IL-4 Signaling Pathway—TYK2—psoriasis	0.000327	0.00145	CbGpPWpGaD
Olopatadine—S100A12—Immune System—ITGAL—psoriasis	0.000323	0.00143	CbGpPWpGaD
Olopatadine—S100B—Activated TLR4 signalling—IL6—psoriasis	0.000317	0.00141	CbGpPWpGaD
Olopatadine—S100A12—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	0.000316	0.0014	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—SOCS1—psoriasis	0.000313	0.00139	CbGpPWpGaD
Olopatadine—Depression—Prednisone—psoriasis	0.000306	0.000737	CcSEcCtD
Olopatadine—S100B—Immune System—ITGAL—psoriasis	0.000305	0.00135	CbGpPWpGaD
Olopatadine—Discomfort—Cyclosporine—psoriasis	0.000305	0.000734	CcSEcCtD
Olopatadine—Visual impairment—Betamethasone—psoriasis	0.000305	0.000734	CcSEcCtD
Olopatadine—Visual impairment—Dexamethasone—psoriasis	0.000305	0.000734	CcSEcCtD
Olopatadine—Erythema—Triamcinolone—psoriasis	0.000303	0.000731	CcSEcCtD
Olopatadine—Dry mouth—Cyclosporine—psoriasis	0.000302	0.000727	CcSEcCtD
Olopatadine—S100A12—Immune System—REL—psoriasis	0.000302	0.00134	CbGpPWpGaD
Olopatadine—Feeling abnormal—Mycophenolic acid—psoriasis	0.000302	0.000726	CcSEcCtD
Olopatadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000301	0.00134	CbGpPWpGaD
Olopatadine—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000299	0.00072	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000299	0.00072	CcSEcCtD
Olopatadine—Ill-defined disorder—Hydrocortisone—psoriasis	0.000299	0.00072	CcSEcCtD
Olopatadine—Diarrhoea—Hydroxyurea—psoriasis	0.000299	0.000719	CcSEcCtD
Olopatadine—S100B—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	0.000298	0.00132	CbGpPWpGaD
Olopatadine—Malaise—Prednisolone—psoriasis	0.000298	0.000716	CcSEcCtD
Olopatadine—Discomfort—Mycophenolate mofetil—psoriasis	0.000298	0.000716	CcSEcCtD
Olopatadine—Dysgeusia—Triamcinolone—psoriasis	0.000297	0.000715	CcSEcCtD
Olopatadine—Oedema—Cyclosporine—psoriasis	0.000296	0.000713	CcSEcCtD
Olopatadine—Eye disorder—Betamethasone—psoriasis	0.000296	0.000712	CcSEcCtD
Olopatadine—Eye disorder—Dexamethasone—psoriasis	0.000296	0.000712	CcSEcCtD
Olopatadine—Dry mouth—Mycophenolate mofetil—psoriasis	0.000295	0.000709	CcSEcCtD
Olopatadine—Infection—Cyclosporine—psoriasis	0.000294	0.000708	CcSEcCtD
Olopatadine—Back pain—Triamcinolone—psoriasis	0.000294	0.000707	CcSEcCtD
Olopatadine—S100A12—Immune System—IFIH1—psoriasis	0.000293	0.0013	CbGpPWpGaD
Olopatadine—Malaise—Hydrocortisone—psoriasis	0.000291	0.0007	CcSEcCtD
Olopatadine—Nervous system disorder—Cyclosporine—psoriasis	0.00029	0.000699	CcSEcCtD
Olopatadine—Body temperature increased—Mycophenolic acid—psoriasis	0.000289	0.000696	CcSEcCtD
Olopatadine—Abdominal pain—Mycophenolic acid—psoriasis	0.000289	0.000696	CcSEcCtD
Olopatadine—Dizziness—Hydroxyurea—psoriasis	0.000289	0.000695	CcSEcCtD
Olopatadine—Oedema—Mycophenolate mofetil—psoriasis	0.000289	0.000695	CcSEcCtD
Olopatadine—Skin disorder—Cyclosporine—psoriasis	0.000288	0.000692	CcSEcCtD
Olopatadine—Infection—Mycophenolate mofetil—psoriasis	0.000287	0.000691	CcSEcCtD
Olopatadine—S100B—Immune System—REL—psoriasis	0.000285	0.00127	CbGpPWpGaD
Olopatadine—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000283	0.000682	CcSEcCtD
Olopatadine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000282	0.00125	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—HLA-B—psoriasis	0.000282	0.00125	CbGpPWpGaD
Olopatadine—Ill-defined disorder—Triamcinolone—psoriasis	0.000282	0.000678	CcSEcCtD
Olopatadine—S100A12—Toll-Like Receptors Cascades—IL6—psoriasis	0.000281	0.00125	CbGpPWpGaD
Olopatadine—Skin disorder—Mycophenolate mofetil—psoriasis	0.00028	0.000675	CcSEcCtD
Olopatadine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000278	0.00124	CbGpPWpGaD
Olopatadine—S100A12—Immune System—HLA-C—psoriasis	0.000278	0.00123	CbGpPWpGaD
Olopatadine—Vomiting—Hydroxyurea—psoriasis	0.000278	0.000669	CcSEcCtD
Olopatadine—Discomfort—Prednisolone—psoriasis	0.000278	0.000668	CcSEcCtD
Olopatadine—S100B—Immune System—IFIH1—psoriasis	0.000277	0.00123	CbGpPWpGaD
Olopatadine—Rash—Hydroxyurea—psoriasis	0.000275	0.000663	CcSEcCtD
Olopatadine—Erythema—Betamethasone—psoriasis	0.000275	0.000663	CcSEcCtD
Olopatadine—Erythema—Dexamethasone—psoriasis	0.000275	0.000663	CcSEcCtD
Olopatadine—Dermatitis—Hydroxyurea—psoriasis	0.000275	0.000662	CcSEcCtD
Olopatadine—S100A12—Immune System—TNFAIP3—psoriasis	0.000274	0.00122	CbGpPWpGaD
Olopatadine—Malaise—Triamcinolone—psoriasis	0.000274	0.000659	CcSEcCtD
Olopatadine—Headache—Hydroxyurea—psoriasis	0.000274	0.000659	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000273	0.000656	CcSEcCtD
Olopatadine—Discomfort—Hydrocortisone—psoriasis	0.000271	0.000653	CcSEcCtD
Olopatadine—Oedema—Prednisolone—psoriasis	0.000269	0.000648	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Methotrexate—psoriasis	0.000267	0.000644	CcSEcCtD
Olopatadine—S100B—Innate Immune System—HLA-B—psoriasis	0.000267	0.00118	CbGpPWpGaD
Olopatadine—S100B—Toll-Like Receptors Cascades—IL6—psoriasis	0.000266	0.00118	CbGpPWpGaD
Olopatadine—Cough—Triamcinolone—psoriasis	0.000265	0.000638	CcSEcCtD
Olopatadine—Dyspnoea—Cyclosporine—psoriasis	0.000264	0.000635	CcSEcCtD
Olopatadine—Somnolence—Cyclosporine—psoriasis	0.000263	0.000633	CcSEcCtD
Olopatadine—Oedema—Hydrocortisone—psoriasis	0.000263	0.000633	CcSEcCtD
Olopatadine—S100B—Immune System—HLA-C—psoriasis	0.000263	0.00117	CbGpPWpGaD
Olopatadine—Asthenia—Mycophenolic acid—psoriasis	0.000263	0.000632	CcSEcCtD
Olopatadine—Infection—Hydrocortisone—psoriasis	0.000261	0.000629	CcSEcCtD
Olopatadine—Nausea—Hydroxyurea—psoriasis	0.000259	0.000625	CcSEcCtD
Olopatadine—S100B—Immune System—TNFAIP3—psoriasis	0.000259	0.00115	CbGpPWpGaD
Olopatadine—Pruritus—Mycophenolic acid—psoriasis	0.000259	0.000623	CcSEcCtD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000259	0.00115	CbGpPWpGaD
Olopatadine—Nervous system disorder—Hydrocortisone—psoriasis	0.000258	0.000621	CcSEcCtD
Olopatadine—Eye disorder—Prednisone—psoriasis	0.000257	0.00062	CcSEcCtD
Olopatadine—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000257	0.00062	CcSEcCtD
Olopatadine—Somnolence—Mycophenolate mofetil—psoriasis	0.000257	0.000618	CcSEcCtD
Olopatadine—Infestation NOS—Methotrexate—psoriasis	0.000256	0.000617	CcSEcCtD
Olopatadine—Infestation—Methotrexate—psoriasis	0.000256	0.000617	CcSEcCtD
Olopatadine—Depression—Methotrexate—psoriasis	0.000256	0.000616	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000256	0.000615	CcSEcCtD
Olopatadine—Skin disorder—Hydrocortisone—psoriasis	0.000256	0.000615	CcSEcCtD
Olopatadine—Ill-defined disorder—Betamethasone—psoriasis	0.000256	0.000615	CcSEcCtD
Olopatadine—Ill-defined disorder—Dexamethasone—psoriasis	0.000256	0.000615	CcSEcCtD
Olopatadine—Discomfort—Triamcinolone—psoriasis	0.000255	0.000615	CcSEcCtD
Olopatadine—Fatigue—Cyclosporine—psoriasis	0.000255	0.000614	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—NFKB1—psoriasis	0.000255	0.00113	CbGpPWpGaD
Olopatadine—Pain—Cyclosporine—psoriasis	0.000253	0.000609	CcSEcCtD
Olopatadine—Dry mouth—Triamcinolone—psoriasis	0.000253	0.000608	CcSEcCtD
Olopatadine—Diarrhoea—Mycophenolic acid—psoriasis	0.00025	0.000603	CcSEcCtD
Olopatadine—S100B—Signaling by ERBB4—IL6—psoriasis	0.00025	0.00111	CbGpPWpGaD
Olopatadine—Conjunctivitis—Methotrexate—psoriasis	0.000249	0.0006	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000249	0.0006	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—CRP—psoriasis	0.000249	0.00111	CbGpPWpGaD
Olopatadine—Immune system disorder—Prednisone—psoriasis	0.000249	0.000599	CcSEcCtD
Olopatadine—Malaise—Betamethasone—psoriasis	0.000248	0.000598	CcSEcCtD
Olopatadine—Malaise—Dexamethasone—psoriasis	0.000248	0.000598	CcSEcCtD
Olopatadine—Oedema—Triamcinolone—psoriasis	0.000248	0.000596	CcSEcCtD
Olopatadine—Pain—Mycophenolate mofetil—psoriasis	0.000247	0.000594	CcSEcCtD
Olopatadine—Infection—Triamcinolone—psoriasis	0.000246	0.000592	CcSEcCtD
Olopatadine—Feeling abnormal—Cyclosporine—psoriasis	0.000244	0.000587	CcSEcCtD
Olopatadine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000244	0.00108	CbGpPWpGaD
Olopatadine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000242	0.000583	CcSEcCtD
Olopatadine—Dizziness—Mycophenolic acid—psoriasis	0.000242	0.000582	CcSEcCtD
Olopatadine—Epistaxis—Methotrexate—psoriasis	0.000242	0.000582	CcSEcCtD
Olopatadine—Erythema—Prednisone—psoriasis	0.00024	0.000577	CcSEcCtD
Olopatadine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000238	0.000573	CcSEcCtD
Olopatadine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000236	0.000568	CcSEcCtD
Olopatadine—S100B—Innate Immune System—CRP—psoriasis	0.000236	0.00105	CbGpPWpGaD
Olopatadine—Abdominal pain—Cyclosporine—psoriasis	0.000234	0.000563	CcSEcCtD
Olopatadine—Body temperature increased—Cyclosporine—psoriasis	0.000234	0.000563	CcSEcCtD
Olopatadine—Vomiting—Mycophenolic acid—psoriasis	0.000233	0.00056	CcSEcCtD
Olopatadine—Discomfort—Dexamethasone—psoriasis	0.000232	0.000558	CcSEcCtD
Olopatadine—Discomfort—Betamethasone—psoriasis	0.000232	0.000558	CcSEcCtD
Olopatadine—Rash—Mycophenolic acid—psoriasis	0.000231	0.000555	CcSEcCtD
Olopatadine—S100A12—Immune System—HLA-E—psoriasis	0.000231	0.00102	CbGpPWpGaD
Olopatadine—Dermatitis—Mycophenolic acid—psoriasis	0.00023	0.000555	CcSEcCtD
Olopatadine—Pain—Prednisolone—psoriasis	0.00023	0.000554	CcSEcCtD
Olopatadine—Headache—Mycophenolic acid—psoriasis	0.000229	0.000552	CcSEcCtD
Olopatadine—HRH1—IL-4 Signaling Pathway—STAT3—psoriasis	0.000229	0.00102	CbGpPWpGaD
Olopatadine—Pharyngitis—Methotrexate—psoriasis	0.000229	0.00055	CcSEcCtD
Olopatadine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000228	0.000549	CcSEcCtD
Olopatadine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000228	0.000549	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—NFKBIA—psoriasis	0.000227	0.00101	CbGpPWpGaD
Olopatadine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000227	0.000547	CcSEcCtD
Olopatadine—Fatigue—Hydrocortisone—psoriasis	0.000227	0.000546	CcSEcCtD
Olopatadine—Vision blurred—Prednisone—psoriasis	0.000226	0.000544	CcSEcCtD
Olopatadine—Pain—Hydrocortisone—psoriasis	0.000225	0.000542	CcSEcCtD
Olopatadine—Oedema—Betamethasone—psoriasis	0.000225	0.000541	CcSEcCtD
Olopatadine—Oedema—Dexamethasone—psoriasis	0.000225	0.000541	CcSEcCtD
Olopatadine—Infection—Betamethasone—psoriasis	0.000223	0.000537	CcSEcCtD
Olopatadine—Infection—Dexamethasone—psoriasis	0.000223	0.000537	CcSEcCtD
Olopatadine—Ill-defined disorder—Prednisone—psoriasis	0.000223	0.000536	CcSEcCtD
Olopatadine—Feeling abnormal—Prednisolone—psoriasis	0.000222	0.000534	CcSEcCtD
Olopatadine—Visual impairment—Methotrexate—psoriasis	0.000222	0.000534	CcSEcCtD
Olopatadine—Dyspnoea—Triamcinolone—psoriasis	0.000221	0.000532	CcSEcCtD
Olopatadine—Nervous system disorder—Dexamethasone—psoriasis	0.00022	0.000531	CcSEcCtD
Olopatadine—Nervous system disorder—Betamethasone—psoriasis	0.00022	0.000531	CcSEcCtD
Olopatadine—Hypersensitivity—Cyclosporine—psoriasis	0.000218	0.000525	CcSEcCtD
Olopatadine—S100B—Immune System—HLA-E—psoriasis	0.000218	0.000967	CbGpPWpGaD
Olopatadine—Nausea—Mycophenolic acid—psoriasis	0.000217	0.000523	CcSEcCtD
Olopatadine—Feeling abnormal—Hydrocortisone—psoriasis	0.000217	0.000522	CcSEcCtD
Olopatadine—Malaise—Prednisone—psoriasis	0.000216	0.000521	CcSEcCtD
Olopatadine—Eye disorder—Methotrexate—psoriasis	0.000215	0.000518	CcSEcCtD
Olopatadine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000215	0.000518	CcSEcCtD
Olopatadine—S100B—Innate Immune System—NFKBIA—psoriasis	0.000215	0.000954	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—HCAR2—psoriasis	0.000214	0.000951	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCL20—psoriasis	0.000214	0.000949	CbGpPWpGaD
Olopatadine—Fatigue—Triamcinolone—psoriasis	0.000214	0.000514	CcSEcCtD
Olopatadine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000213	0.000512	CcSEcCtD
Olopatadine—Asthenia—Cyclosporine—psoriasis	0.000212	0.000511	CcSEcCtD
Olopatadine—Pain—Triamcinolone—psoriasis	0.000212	0.00051	CcSEcCtD
Olopatadine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00021	0.000932	CbGpPWpGaD
Olopatadine—Pruritus—Cyclosporine—psoriasis	0.000209	0.000504	CcSEcCtD
Olopatadine—Immune system disorder—Methotrexate—psoriasis	0.000208	0.000501	CcSEcCtD
Olopatadine—Body temperature increased—Hydrocortisone—psoriasis	0.000208	0.000501	CcSEcCtD
Olopatadine—Abdominal pain—Hydrocortisone—psoriasis	0.000208	0.000501	CcSEcCtD
Olopatadine—Mediastinal disorder—Methotrexate—psoriasis	0.000207	0.000499	CcSEcCtD
Olopatadine—Asthenia—Mycophenolate mofetil—psoriasis	0.000207	0.000499	CcSEcCtD
Olopatadine—Pruritus—Mycophenolate mofetil—psoriasis	0.000204	0.000492	CcSEcCtD
Olopatadine—Feeling abnormal—Triamcinolone—psoriasis	0.000204	0.000491	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000203	0.000488	CcSEcCtD
Olopatadine—Diarrhoea—Cyclosporine—psoriasis	0.000203	0.000488	CcSEcCtD
Olopatadine—Discomfort—Prednisone—psoriasis	0.000202	0.000486	CcSEcCtD
Olopatadine—Erythema—Methotrexate—psoriasis	0.0002	0.000482	CcSEcCtD
Olopatadine—Hypersensitivity—Prednisolone—psoriasis	0.000198	0.000478	CcSEcCtD
Olopatadine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000198	0.000476	CcSEcCtD
Olopatadine—HRH1—GPCR ligand binding—CCL20—psoriasis	0.000197	0.000874	CbGpPWpGaD
Olopatadine—Dysgeusia—Methotrexate—psoriasis	0.000196	0.000472	CcSEcCtD
Olopatadine—Body temperature increased—Triamcinolone—psoriasis	0.000196	0.000471	CcSEcCtD
Olopatadine—Dizziness—Cyclosporine—psoriasis	0.000196	0.000471	CcSEcCtD
Olopatadine—Oedema—Prednisone—psoriasis	0.000196	0.000471	CcSEcCtD
Olopatadine—HRH1—Signaling by GPCR—HCAR2—psoriasis	0.000195	0.000863	CbGpPWpGaD
Olopatadine—Infection—Prednisone—psoriasis	0.000194	0.000468	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000194	0.000467	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000194	0.000467	CcSEcCtD
Olopatadine—Back pain—Methotrexate—psoriasis	0.000194	0.000467	CcSEcCtD
Olopatadine—Hypersensitivity—Hydrocortisone—psoriasis	0.000194	0.000467	CcSEcCtD
Olopatadine—Fatigue—Dexamethasone—psoriasis	0.000194	0.000466	CcSEcCtD
Olopatadine—Fatigue—Betamethasone—psoriasis	0.000194	0.000466	CcSEcCtD
Olopatadine—S100A12—Immune System—SOCS1—psoriasis	0.000193	0.000854	CbGpPWpGaD
Olopatadine—Pain—Betamethasone—psoriasis	0.000192	0.000463	CcSEcCtD
Olopatadine—Pain—Dexamethasone—psoriasis	0.000192	0.000463	CcSEcCtD
Olopatadine—Nervous system disorder—Prednisone—psoriasis	0.000192	0.000462	CcSEcCtD
Olopatadine—Dizziness—Mycophenolate mofetil—psoriasis	0.000191	0.00046	CcSEcCtD
Olopatadine—Skin disorder—Prednisone—psoriasis	0.00019	0.000458	CcSEcCtD
Olopatadine—Vision blurred—Methotrexate—psoriasis	0.000189	0.000455	CcSEcCtD
Olopatadine—Asthenia—Hydrocortisone—psoriasis	0.000189	0.000454	CcSEcCtD
Olopatadine—Vomiting—Cyclosporine—psoriasis	0.000188	0.000453	CcSEcCtD
Olopatadine—Rash—Cyclosporine—psoriasis	0.000187	0.000449	CcSEcCtD
Olopatadine—Dermatitis—Cyclosporine—psoriasis	0.000186	0.000449	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—TYK2—psoriasis	0.000186	0.000826	CbGpPWpGaD
Olopatadine—Pruritus—Hydrocortisone—psoriasis	0.000186	0.000448	CcSEcCtD
Olopatadine—Ill-defined disorder—Methotrexate—psoriasis	0.000186	0.000448	CcSEcCtD
Olopatadine—Headache—Cyclosporine—psoriasis	0.000185	0.000446	CcSEcCtD
Olopatadine—Feeling abnormal—Dexamethasone—psoriasis	0.000185	0.000446	CcSEcCtD
Olopatadine—Feeling abnormal—Betamethasone—psoriasis	0.000185	0.000446	CcSEcCtD
Olopatadine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000184	0.000442	CcSEcCtD
Olopatadine—Gastrointestinal pain—Betamethasone—psoriasis	0.000184	0.000442	CcSEcCtD
Olopatadine—Vomiting—Mycophenolate mofetil—psoriasis	0.000184	0.000442	CcSEcCtD
Olopatadine—Hypersensitivity—Triamcinolone—psoriasis	0.000182	0.000439	CcSEcCtD
Olopatadine—S100B—Immune System—SOCS1—psoriasis	0.000182	0.000808	CbGpPWpGaD
Olopatadine—Rash—Mycophenolate mofetil—psoriasis	0.000182	0.000438	CcSEcCtD
Olopatadine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000182	0.000438	CcSEcCtD
Olopatadine—Headache—Mycophenolate mofetil—psoriasis	0.000181	0.000435	CcSEcCtD
Olopatadine—Malaise—Methotrexate—psoriasis	0.000181	0.000435	CcSEcCtD
Olopatadine—Diarrhoea—Hydrocortisone—psoriasis	0.00018	0.000433	CcSEcCtD
Olopatadine—Dizziness—Prednisolone—psoriasis	0.000178	0.000429	CcSEcCtD
Olopatadine—Asthenia—Triamcinolone—psoriasis	0.000178	0.000428	CcSEcCtD
Olopatadine—Abdominal pain—Dexamethasone—psoriasis	0.000178	0.000428	CcSEcCtD
Olopatadine—Abdominal pain—Betamethasone—psoriasis	0.000178	0.000428	CcSEcCtD
Olopatadine—Body temperature increased—Betamethasone—psoriasis	0.000178	0.000428	CcSEcCtD
Olopatadine—Body temperature increased—Dexamethasone—psoriasis	0.000178	0.000428	CcSEcCtD
Olopatadine—S100B—Innate Immune System—TYK2—psoriasis	0.000176	0.000781	CbGpPWpGaD
Olopatadine—Nausea—Cyclosporine—psoriasis	0.000176	0.000423	CcSEcCtD
Olopatadine—Pruritus—Triamcinolone—psoriasis	0.000175	0.000422	CcSEcCtD
Olopatadine—Cough—Methotrexate—psoriasis	0.000175	0.000421	CcSEcCtD
Olopatadine—Dizziness—Hydrocortisone—psoriasis	0.000174	0.000419	CcSEcCtD
Olopatadine—Nausea—Mycophenolate mofetil—psoriasis	0.000172	0.000413	CcSEcCtD
Olopatadine—S100A12—Immune System—CD8A—psoriasis	0.000171	0.000758	CbGpPWpGaD
Olopatadine—Rash—Prednisolone—psoriasis	0.00017	0.000409	CcSEcCtD
Olopatadine—Dermatitis—Prednisolone—psoriasis	0.00017	0.000408	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000169	0.000408	CcSEcCtD
Olopatadine—Fatigue—Prednisone—psoriasis	0.000169	0.000406	CcSEcCtD
Olopatadine—Headache—Prednisolone—psoriasis	0.000169	0.000406	CcSEcCtD
Olopatadine—Discomfort—Methotrexate—psoriasis	0.000169	0.000406	CcSEcCtD
Olopatadine—S100A12—Innate Immune System—CD4—psoriasis	0.000168	0.000747	CbGpPWpGaD
Olopatadine—Vomiting—Hydrocortisone—psoriasis	0.000167	0.000403	CcSEcCtD
Olopatadine—Rash—Hydrocortisone—psoriasis	0.000166	0.000399	CcSEcCtD
Olopatadine—Dermatitis—Hydrocortisone—psoriasis	0.000166	0.000399	CcSEcCtD
Olopatadine—Headache—Hydrocortisone—psoriasis	0.000165	0.000397	CcSEcCtD
Olopatadine—S100A12—Immune System—HLA-B—psoriasis	0.000164	0.000729	CbGpPWpGaD
Olopatadine—Dizziness—Triamcinolone—psoriasis	0.000164	0.000394	CcSEcCtD
Olopatadine—Infection—Methotrexate—psoriasis	0.000163	0.000391	CcSEcCtD
Olopatadine—S100B—Immune System—CD8A—psoriasis	0.000161	0.000717	CbGpPWpGaD
Olopatadine—Feeling abnormal—Prednisone—psoriasis	0.000161	0.000388	CcSEcCtD
Olopatadine—Asthenia—Betamethasone—psoriasis	0.000161	0.000388	CcSEcCtD
Olopatadine—Asthenia—Dexamethasone—psoriasis	0.000161	0.000388	CcSEcCtD
Olopatadine—Nervous system disorder—Methotrexate—psoriasis	0.00016	0.000386	CcSEcCtD
Olopatadine—Gastrointestinal pain—Prednisone—psoriasis	0.00016	0.000385	CcSEcCtD
Olopatadine—Nausea—Prednisolone—psoriasis	0.00016	0.000385	CcSEcCtD
Olopatadine—S100B—Innate Immune System—CD4—psoriasis	0.000159	0.000707	CbGpPWpGaD
Olopatadine—Pruritus—Dexamethasone—psoriasis	0.000159	0.000383	CcSEcCtD
Olopatadine—Pruritus—Betamethasone—psoriasis	0.000159	0.000383	CcSEcCtD
Olopatadine—Skin disorder—Methotrexate—psoriasis	0.000159	0.000382	CcSEcCtD
Olopatadine—Vomiting—Triamcinolone—psoriasis	0.000157	0.000379	CcSEcCtD
Olopatadine—Nausea—Hydrocortisone—psoriasis	0.000156	0.000376	CcSEcCtD
Olopatadine—Rash—Triamcinolone—psoriasis	0.000156	0.000376	CcSEcCtD
Olopatadine—Dermatitis—Triamcinolone—psoriasis	0.000156	0.000376	CcSEcCtD
Olopatadine—S100B—Immune System—HLA-B—psoriasis	0.000155	0.000689	CbGpPWpGaD
Olopatadine—Headache—Triamcinolone—psoriasis	0.000155	0.000374	CcSEcCtD
Olopatadine—Body temperature increased—Prednisone—psoriasis	0.000155	0.000372	CcSEcCtD
Olopatadine—Abdominal pain—Prednisone—psoriasis	0.000155	0.000372	CcSEcCtD
Olopatadine—Diarrhoea—Betamethasone—psoriasis	0.000154	0.00037	CcSEcCtD
Olopatadine—Diarrhoea—Dexamethasone—psoriasis	0.000154	0.00037	CcSEcCtD
Olopatadine—S100A12—Immune System—HLA-A—psoriasis	0.000152	0.000675	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—JUN—psoriasis	0.000151	0.000669	CbGpPWpGaD
Olopatadine—Dizziness—Dexamethasone—psoriasis	0.000149	0.000358	CcSEcCtD
Olopatadine—Dizziness—Betamethasone—psoriasis	0.000149	0.000358	CcSEcCtD
Olopatadine—Nausea—Triamcinolone—psoriasis	0.000147	0.000354	CcSEcCtD
Olopatadine—Dyspnoea—Methotrexate—psoriasis	0.000146	0.000351	CcSEcCtD
Olopatadine—Somnolence—Methotrexate—psoriasis	0.000145	0.00035	CcSEcCtD
Olopatadine—S100A12—Immune System—CRP—psoriasis	0.000145	0.000644	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—NFKB1—psoriasis	0.000145	0.000644	CbGpPWpGaD
Olopatadine—Hypersensitivity—Prednisone—psoriasis	0.000144	0.000347	CcSEcCtD
Olopatadine—S100B—Immune System—HLA-A—psoriasis	0.000144	0.000639	CbGpPWpGaD
Olopatadine—Vomiting—Betamethasone—psoriasis	0.000143	0.000344	CcSEcCtD
Olopatadine—Vomiting—Dexamethasone—psoriasis	0.000143	0.000344	CcSEcCtD
Olopatadine—S100B—Innate Immune System—JUN—psoriasis	0.000143	0.000632	CbGpPWpGaD
Olopatadine—Rash—Betamethasone—psoriasis	0.000142	0.000341	CcSEcCtD
Olopatadine—Rash—Dexamethasone—psoriasis	0.000142	0.000341	CcSEcCtD
Olopatadine—Dermatitis—Dexamethasone—psoriasis	0.000142	0.000341	CcSEcCtD
Olopatadine—Dermatitis—Betamethasone—psoriasis	0.000142	0.000341	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Methotrexate—psoriasis	0.000141	0.00034	CcSEcCtD
Olopatadine—Fatigue—Methotrexate—psoriasis	0.000141	0.000339	CcSEcCtD
Olopatadine—Headache—Dexamethasone—psoriasis	0.000141	0.000339	CcSEcCtD
Olopatadine—Headache—Betamethasone—psoriasis	0.000141	0.000339	CcSEcCtD
Olopatadine—Asthenia—Prednisone—psoriasis	0.00014	0.000338	CcSEcCtD
Olopatadine—Pain—Methotrexate—psoriasis	0.00014	0.000337	CcSEcCtD
Olopatadine—S100A12—Immune System—HLA-DRB1—psoriasis	0.000139	0.000617	CbGpPWpGaD
Olopatadine—Pruritus—Prednisone—psoriasis	0.000138	0.000333	CcSEcCtD
Olopatadine—S100B—Immune System—CRP—psoriasis	0.000137	0.000609	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—NFKB1—psoriasis	0.000137	0.000609	CbGpPWpGaD
Olopatadine—Feeling abnormal—Methotrexate—psoriasis	0.000135	0.000324	CcSEcCtD
Olopatadine—Diarrhoea—Prednisone—psoriasis	0.000134	0.000322	CcSEcCtD
Olopatadine—Gastrointestinal pain—Methotrexate—psoriasis	0.000134	0.000322	CcSEcCtD
Olopatadine—Nausea—Betamethasone—psoriasis	0.000133	0.000321	CcSEcCtD
Olopatadine—Nausea—Dexamethasone—psoriasis	0.000133	0.000321	CcSEcCtD
Olopatadine—S100A12—Immune System—ICAM1—psoriasis	0.000133	0.000592	CbGpPWpGaD
Olopatadine—S100A12—Immune System—NFKBIA—psoriasis	0.000132	0.000588	CbGpPWpGaD
Olopatadine—S100B—Immune System—HLA-DRB1—psoriasis	0.000131	0.000583	CbGpPWpGaD
Olopatadine—Dizziness—Prednisone—psoriasis	0.000129	0.000312	CcSEcCtD
Olopatadine—Abdominal pain—Methotrexate—psoriasis	0.000129	0.000311	CcSEcCtD
Olopatadine—Body temperature increased—Methotrexate—psoriasis	0.000129	0.000311	CcSEcCtD
Olopatadine—S100B—Immune System—ICAM1—psoriasis	0.000126	0.00056	CbGpPWpGaD
Olopatadine—S100B—Immune System—NFKBIA—psoriasis	0.000125	0.000556	CbGpPWpGaD
Olopatadine—Vomiting—Prednisone—psoriasis	0.000124	0.0003	CcSEcCtD
Olopatadine—Rash—Prednisone—psoriasis	0.000123	0.000297	CcSEcCtD
Olopatadine—Dermatitis—Prednisone—psoriasis	0.000123	0.000297	CcSEcCtD
Olopatadine—Headache—Prednisone—psoriasis	0.000123	0.000295	CcSEcCtD
Olopatadine—Hypersensitivity—Methotrexate—psoriasis	0.000121	0.00029	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—SOCS1—psoriasis	0.000118	0.000522	CbGpPWpGaD
Olopatadine—Asthenia—Methotrexate—psoriasis	0.000117	0.000283	CcSEcCtD
Olopatadine—Nausea—Prednisone—psoriasis	0.000116	0.00028	CcSEcCtD
Olopatadine—Pruritus—Methotrexate—psoriasis	0.000116	0.000279	CcSEcCtD
Olopatadine—HRH1—Signaling Pathways—HCAR2—psoriasis	0.000115	0.00051	CbGpPWpGaD
Olopatadine—Diarrhoea—Methotrexate—psoriasis	0.000112	0.000269	CcSEcCtD
Olopatadine—HRH1—GPCR downstream signaling—CCL20—psoriasis	0.000111	0.000494	CbGpPWpGaD
Olopatadine—S100A12—Immune System—TYK2—psoriasis	0.000108	0.000481	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000108	0.000481	CbGpPWpGaD
Olopatadine—Dizziness—Methotrexate—psoriasis	0.000108	0.00026	CcSEcCtD
Olopatadine—Vomiting—Methotrexate—psoriasis	0.000104	0.00025	CcSEcCtD
Olopatadine—Rash—Methotrexate—psoriasis	0.000103	0.000248	CcSEcCtD
Olopatadine—Dermatitis—Methotrexate—psoriasis	0.000103	0.000248	CcSEcCtD
Olopatadine—S100B—Immune System—TYK2—psoriasis	0.000103	0.000455	CbGpPWpGaD
Olopatadine—Headache—Methotrexate—psoriasis	0.000102	0.000247	CcSEcCtD
Olopatadine—S100A12—Immune System—IFNG—psoriasis	0.000102	0.000451	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CCL20—psoriasis	0.000101	0.000448	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TAGAP—psoriasis	9.97e-05	0.000442	CbGpPWpGaD
Olopatadine—S100A12—Immune System—CD4—psoriasis	9.81e-05	0.000435	CbGpPWpGaD
Olopatadine—Nausea—Methotrexate—psoriasis	9.72e-05	0.000234	CcSEcCtD
Olopatadine—S100B—Immune System—IFNG—psoriasis	9.6e-05	0.000426	CbGpPWpGaD
Olopatadine—S100B—Immune System—CD4—psoriasis	9.27e-05	0.000412	CbGpPWpGaD
Olopatadine—S100A12—Innate Immune System—IL6—psoriasis	9.11e-05	0.000404	CbGpPWpGaD
Olopatadine—S100A12—Immune System—JUN—psoriasis	8.78e-05	0.00039	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—APOE—psoriasis	8.69e-05	0.000385	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—LEP—psoriasis	8.69e-05	0.000385	CbGpPWpGaD
Olopatadine—S100B—Innate Immune System—IL6—psoriasis	8.61e-05	0.000382	CbGpPWpGaD
Olopatadine—S100A12—Immune System—NFKB1—psoriasis	8.45e-05	0.000375	CbGpPWpGaD
Olopatadine—S100B—Immune System—JUN—psoriasis	8.3e-05	0.000368	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NFKBIA—psoriasis	8.09e-05	0.000359	CbGpPWpGaD
Olopatadine—S100B—Immune System—NFKB1—psoriasis	7.99e-05	0.000355	CbGpPWpGaD
Olopatadine—S100A12—Immune System—STAT3—psoriasis	7.59e-05	0.000337	CbGpPWpGaD
Olopatadine—S100B—Immune System—STAT3—psoriasis	7.18e-05	0.000319	CbGpPWpGaD
Olopatadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	6.98e-05	0.00031	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TYK2—psoriasis	6.63e-05	0.000294	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCL20—psoriasis	5.97e-05	0.000265	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CXCL8—psoriasis	5.77e-05	0.000256	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NDUFA5—psoriasis	5.68e-05	0.000252	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—JUN—psoriasis	5.37e-05	0.000238	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CXCL8—psoriasis	5.32e-05	0.000236	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL6—psoriasis	5.3e-05	0.000235	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	5.3e-05	0.000235	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—NFKB1—psoriasis	5.17e-05	0.000229	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL6—psoriasis	5.02e-05	0.000223	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP2S1—psoriasis	4.83e-05	0.000214	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—VEGFA—psoriasis	4.69e-05	0.000208	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—STAT3—psoriasis	4.64e-05	0.000206	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TP53—psoriasis	3.54e-05	0.000157	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SOCS1—psoriasis	3.29e-05	0.000146	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL6—psoriasis	3.24e-05	0.000144	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—TYK2—psoriasis	3.13e-05	0.000139	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CXCL8—psoriasis	3.01e-05	0.000133	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CXCL8—psoriasis	2.73e-05	0.000121	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LEP—psoriasis	2.43e-05	0.000108	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—APOE—psoriasis	2.43e-05	0.000108	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CARM1—psoriasis	2.36e-05	0.000105	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NFKBIA—psoriasis	2.26e-05	0.0001	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TYK2—psoriasis	1.85e-05	8.22e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCL8—psoriasis	1.61e-05	7.15e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL6—psoriasis	1.53e-05	6.8e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—JUN—psoriasis	1.5e-05	6.65e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CAT—psoriasis	1.45e-05	6.44e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NFKB1—psoriasis	1.44e-05	6.4e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VEGFA—psoriasis	1.31e-05	5.81e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—STAT3—psoriasis	1.3e-05	5.75e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—APOE—psoriasis	1.13e-05	5e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TP53—psoriasis	9.89e-06	4.39e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PPARG—psoriasis	9.82e-06	4.36e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL6—psoriasis	9.06e-06	4.02e-05	CbGpPWpGaD
